Market: NASD |
Currency: USD
Address: 825 Industrial Road
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
📈 Allakos Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$0.40
-
Upside/Downside from Analyst Target:
22.70%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Allakos Inc.
| Date | Reported EPS |
|---|
| 2025-05-07 | -0.29 |
| 2025-03-12 | -0.26 |
| 2024-11-06 | -0.21 |
| 2024-08-07 | -0.3 |
| 2024-05-09 | -0.5 |
| 2024-03-14 | -0.71 |
| 2023-11-13 | -0.52 |
| 2023-08-09 | -0.41 |
| 2023-05-09 | -0.49 |
| 2023-03-06 | -0.5 |
| 2022-11-07 | -0.53 |
| 2022-08-04 | -0.9 |
| 2022-05-06 | -3.6 |
| 2022-03-01 | -1.73 |
| 2021-11-08 | -1.16 |
| 2021-08-09 | -1.07 |
| 2021-05-10 | -1.04 |
| 2021-03-01 | -0.86 |
| 2020-11-09 | -0.86 |
| 2020-08-10 | -0.8 |
| 2020-05-11 | -0.57 |
| 2020-02-25 | -0.51 |
| 2019-11-12 | -0.47 |
| 2019-08-05 | -0.44 |
| 2019-05-08 | -0.47 |
📰 Related News & Research
No related articles found for "allakos inc".
